13 unknown. 13 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Unknown 13 |
| Phase 1 | 4 | Unknown 4 |
Follow Chronic Hepatitis B: new trials by email Literature Review of Chronic Hepatitis B trials Research Report on Chronic Hepatitis B
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial to Evaluate the Efficacy and Safety of TQA3810 Tablets in Combination/Non Combination With Nucleoside (Acid) Analogues in Patients With Primary/Treated Chronic Hepatitis B TQA3810 tablets+NUC, Placebo+NUC - Chronic Hepatitis B | Phase 2 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 90 | 2024-03-20 | 2024-08-22 |
| A Study to Assess the Efficacy and Safety of Burfiralimab(hzVSF-v13) and OAD (Oral Antiviral Drug) Standard of care - Chronic Hepatitis B | Phase 2 | Unknown | ImmuneMed, Inc. | 32 | 2022-01-11 | 2023-06-15 |
| A Study of TQ-A3334 Combined With Entecavir in the Treatment of Chronic Hepatitis B TQ-A3334, Placebo, Entecavir Tablet - Chronic Hepatitis B | Phase 2 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 12 | 2019-11-18 | 2019-12-16 |
| An Study to Evaluate Safety and Efficacy of QL-007 Tablets in Combination With Tenofovir in Naive Patients With Chronic Hepatitis b TDF tablet, QL-007 - Chronic Hepatitis b | Phase 2 | Unknown | Qilu Pharmaceutical Co., Ltd. | 100 | 2019-07-26 | 2019-11-12 |
| An Study to Evaluate Safety and Efficacy of QL-007 Tablets in Combination With Entecavir or Tenofovir in Patients With Chronic Hepatitis b Who Have Received Nucleoside (Acid) Therapy TDF tablet, Entecavir Tablet, QL-007 - Chronic Hepatitis b | Phase 2 | Unknown | Qilu Pharmaceutical Co., Ltd. | 60 | 2019-07-26 | 2019-11-08 |
| A Clinical Trial on Hepatitis B Vaccine Activated-Dendritic Cells Combined With Anti-HBV Drugs in CHB HPDC-T cells & Entecavir, Entecavir, HPDC-T cells & IFN-a-2a - Chronic Hepatitis B | Phase 1 / Phase 2 | Unknown | Third Affiliated Hospital, Sun Yat-Sen University | 450 | 2015-11-01 | 2015-11-26 |
| The Treatment With HBIG+GM-CSF+HBV Vaccine for Chronic Hepatitis B Patients With HBeAg Seroconversion Drug, GM-CSF control - Chronic Hepatitis B | Phase 1 / Phase 2 | Unknown | Beijing 302 Hospital | 40 | 2013-06-01 | 2013-07-24 |
| The Safety and Dose-range Study of Metacavir Enteric-coated Capsules in Patients With Chronic Hepatitis B Metacavir Enteric-coated Capsules 80mg, Metacavir Enteric-coated Capsules 160mg, Metacavir Enteric-coated Capsules 320mg - Chronic Hepatitis B | Phase 2 | Unknown | Guangzhou Yipinhong Pharmaceutical CO.,LTD | 180 | 2012-12-01 | 2016-11-22 |
| Pegylated Interferon and Entecavir Combination in Chronic Hepatitis B (CHB) Pegalyted interferon, Entecavir - Chronic Hepatitis B | Phase 1 / Phase 2 | Unknown | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 20 | 2012-03-01 | 2012-05-02 |
| Efficacy and Safety of Dual-plasmid Hepatitis B Virus DNA Vaccine in Chronic Hepatitis B Patients HBV DNA vaccine, Placebo - Chronic Hepatitis B | Phase 2 | Unknown | Fuqiang Yang | 240 | 2011-09-01 | 2011-12-08 |
| Long-term Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis B LB80380, Entecavir 0.5 mg - Chronic Hepatitis B | Phase 2 | Unknown | LG Life Sciences | 115 | 2010-08-01 | 2012-04-16 |
| Dose Escalation of Interleukin-1 (IL-7) Added on Antiviral Treatment and Vaccination in HBeAg-negative Chronic Hepatitis B Virus (HBV) Infected Patients CYT107+GenHevac+entecavir or tenofovir, CYT107+ entecavir or tenofovir - Chronic Hepatitis B | Phase 1 / Phase 2 | Unknown | Cytheris SA | 24 | 2009-12-01 | 2012-10-18 |
| 4-Methylumbelliferone as a Treatment for Chronic HBV/HCV 4-Methylumbelliferone (Heparvit®) - Chronic Hepatitis C, Chronic Hepatitis B | Phase 2 | Unknown | MTmedical Institute of Health | 160 | 2005-09-01 | 2006-09-11 |
Hepatitis B, Chronic (13) · Hepatitis B (2) · Acquired Immunodeficiency Syndrome (1) · Heartburn (1) · Hepatitis (1) · Hepatitis C (1) · Hepatitis C, Chronic (1) · Hepatitis, Chronic (1) · Liver Diseases (1) · Virus Diseases (1)
Blood-Borne Infections (13) · Chronic Disease (13) · Communicable Diseases (13) · DNA Virus Infections (13) · Digestive System Diseases (13) · Disease Attributes (13) · Hepadnaviridae Infections (13) · Hepatitis, Viral, Human (13) · Infections (13) · Pathologic Processes (13) · Pathological Conditions, Signs and Symptoms (13) · Hepatitis (12) · Hepatitis, Chronic (12) · Liver Diseases (12) · Virus Diseases (12)
entecavir (5) · Tenofovir (2) · peginterferon alfa-2a (2) · ((1-((2-amino-9H-purin-9-yl)methyl)cyclopropyl)oxy)methylphosphonic acid dipivoxyl (1) · Drug and Narcotic Control (1) · Hymecromone (1) · Pharmaceutical Preparations (1) · Standard of Care (1) · Telbivudine (1) · adefovir dipivoxil (1)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (2) · Qilu Pharmaceutical Co., Ltd. (2) · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (1) · Beijing 302 Hospital (1) · Cytheris SA (1) · Fuqiang Yang (1) · Guangzhou Yipinhong Pharmaceutical CO.,LTD (1) · ImmuneMed, Inc. (1) · LG Life Sciences (1) · MTmedical Institute of Health (1) · Third Affiliated Hospital, Sun Yat-Sen University (1)
China (8) · South Korea (2) · Bangladesh (1) · France (1) · Italy (1) · United States (1)
Jinlin Hou, PhD (2) · Junqi Niu, PhD (2) · Anastacio M Hoyumpa, Prof. M.D. (1) · Charles T Leach, Prof. M.D. (1) · Christophe Hezode (1) · Dubravko Pavlin, PhD (1) · Fu-Sheng Wang, M.D. (1) · Joon Hyeok Lee, M.D. Ph.D. (1) · Jun Li (1) · Lubiao Chen, MD.&PHD. (1) · Mamun A Mahtab, MSc MD FACG (1) · Maorong Wang (1) · Pietro Andreone (1) · Yanlin Yu (1) · Yongfeng Yang (1)
PMID 17302367, PMID 18808318, PMID 19223649, PMID 20091678, PMID 37055910
2009 (1)